Connected With Latham

97 Episoder

1. Episode 57 – Drug Pricing: What Trends Emerged from the 2023 Medicaid Drug Rebate Program Summit?

   Publisert: 20.10.2023
2. Episode 56 – M&A Views: Avoiding Buyer’s Remorse in M&A Deals

   Publisert: 27.9.2023
3. Episode 55 – Insurtech: What Should Startups Do After Receiving FCA Authorization?

   Publisert: 21.9.2023
4. Episode 54 – Drug Pricing: Focus on Best Price — CMS Proposed Rule, Inflation Reduction Act

   Publisert: 15.9.2023
5. Episode 53 – Energy & Infrastructure: Can Sustainable Finance Fuel the Energy Transition?

   Publisert: 30.8.2023
6. Episode 52 – Drug Pricing: Could a Single Reference Price Apply Across a Therapeutic Class?

   Publisert: 21.8.2023
7. Episode 51 – Drug Pricing: Final IRA Price Negotiation Guidance – How CMS Addressed the Part D/B Problem

   Publisert: 31.7.2023
8. Episode 50 – PE Views: Under New Reforms, Is the Customer Always Right?

   Publisert: 14.7.2023
9. Episode 49 – PE Views: Will Greenwashing Rain on the UK PE Parade?

   Publisert: 20.6.2023
10. Episode 48 – M&A Views: Will UK-Bound M&A Need to Come to US Terms?

    Publisert: 27.4.2023
11. Episode 47 – Real Estate Realities in Europe: Expensive Money and the Power of Private Equity

    Publisert: 17.4.2023
12. Episode 46 – PE Views: PE Must Strike the Right Balance With Unions

    Publisert: 31.3.2023
13. Episode 45 – Will Insurtech Reach New Heights in 2023?

    Publisert: 8.3.2023
14. Episode 44 – PE Views: Private Equity Looks to Share-Based Schemes to Incentivise Non-Managerial Staff

    Publisert: 20.1.2023
15. Episode 43 – Energy & Infrastructure: The Drivers and Opportunities of Asia’s Digital Infrastructure Boom

    Publisert: 1.11.2022
16. Episode 42 – PE Views: Has Rethinking Cannabis Sparked PE Interest?

    Publisert: 11.7.2022
17. Episode 41 – PE Views: Why Do Music Deals Sound So Attractive to PE?

    Publisert: 9.6.2022
18. Episode 40 – PE Views: Could PE Benefit From the Universal Adoption of “Super Senior” RCFs in Leveraged Financings?

    Publisert: 28.4.2022
19. Episode 39 – New FDA Commissioner Dr. Califf: What His Appointment Means for the Regulated Industry and What to Watch for in 2022

    Publisert: 15.2.2022
20. Episode 38 – PE Views: How are ESG Regulatory Reforms and Investor Focus Shaping the Market?

    Publisert: 14.2.2022